Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype
2004 · Journal of Clinical Investigation · 286 citations
https://doi.org/10.1172/jci21378
D
Diane R. Bielenberg
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
209
Papers
7.9K
Citations
45
h-index
80
i10-index
Diane R. Bielenberg is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Angiogenesis and VEGF in Cancer & Cancer Cells and Metastasis & Lymphatic System and Diseases. The author has an h-index of 45, co-authored 178 publications.
ORCID: 0000-0003-3905-0059Papers by this author
worksDIAPH3 governs the cellular transition to the amoeboid tumour phenotype
2012 · EMBO Molecular Medicine · 105 citations
https://doi.org/10.1002/emmm.201200242
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells
2008 · Microvascular Research · 53 citations
https://doi.org/10.1016/j.mvr.2008.01.002
Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer
2014 · BMC Cancer · 50 citations
https://doi.org/10.1186/1471-2407-14-387
Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain
2021 · Scientific Reports · 8 citations
https://doi.org/10.1038/s41598-021-91127-0
Systemic heparin administration impairs lung development in neonatal mice
2025 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-025-99831-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat